Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
Year: 2021
Type: article
Source: Gynecologic Oncology
Authors: William Bradley, Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe Sonke, Charlie Gourley, Susana Banerjee, Amit Oza, Antonio González-Martín, Carol Aghajanian, Theresa Cain, Elizabeth Lowe, Paul DiSilvestro
Institutions: Medical College of Wisconsin, OU Health Stephenson Cancer Center, European Institute of Oncology, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Samsung Medical Center, Sungkyunkwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, UNSW Sydney, Prince of Wales Hospital, City Clinical Oncology Center, Institut Bergonié, Institut Gustave Roussy, Fondation Gustave Roussy, The Netherlands Cancer Institute, Edinburgh Cancer Research, University of Edinburgh, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Princess Margaret Cancer Centre, Clinica Universidad de Navarra, Memorial Sloan Kettering Cancer Center, AstraZeneca (United Kingdom), Women & Infants Hospital of Rhode Island
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3195520437